Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Cost Effectiveness and Resource Allocation : C/E
|
May 19, 2018
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
Dhvani Shah, Maurice Driessen, Nancy Risebrough, et al.
Drugs & Aging
|
June 29, 2018
Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials
Riju Ray, Lee Tombs, Michael J Asmus, et al.
Respiratory Medicine
|
September 19, 2009
Budesonide/formoterol maintenance and reliever therapy versus conventional best practice
Pascal Demoly, Renaud Louis, Ulrik Søes-Petersen, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 14, 2019
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
Victoria Federico Paly, Ian Naya, Necdet B Gunsoy, et al.
Respiratory Research
|
June 4, 2020
Measuring disease activity in COPD: is clinically important deterioration the answer?
Dave Singh, Gerard J Criner, Ian Naya, et al.
The Journal of Allergy and Clinical Immunology
|
May 8, 2002
Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction
Barbro Dahlén, Annika Roquet, Mark D Inman, et al.
American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions
|
January 15, 2004
Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma
Eric D Bateman, Theo A Bantje, Maria João Gomes, et al.
The Journal of Allergy and Clinical Immunology
|
April 17, 2009
Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol
Ian D Pavord, Peter K Jeffery, Yusheng Qiu, et al.
Pulmonary Therapy
|
February 7, 2020
Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
Bernardino Alcázar Navarrete, Isabelle Boucot, Ian Naya, et al.
ERJ Open Research
|
October 11, 2018
Preventing clinically important deterioration with single-inhaler triple therapy in COPD
Ian Naya, Chris Compton, Afisi S Ismaila, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Cost Effectiveness and Resource Allocation : C/E
|
May 19, 2018
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
Dhvani Shah, Maurice Driessen, Nancy Risebrough, et al.
Drugs & Aging
|
June 29, 2018
Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials
Riju Ray, Lee Tombs, Michael J Asmus, et al.
Respiratory Medicine
|
September 19, 2009
Budesonide/formoterol maintenance and reliever therapy versus conventional best practice
Pascal Demoly, Renaud Louis, Ulrik Søes-Petersen, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 14, 2019
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
Victoria Federico Paly, Ian Naya, Necdet B Gunsoy, et al.
Respiratory Research
|
June 4, 2020
Measuring disease activity in COPD: is clinically important deterioration the answer?
Dave Singh, Gerard J Criner, Ian Naya, et al.
The Journal of Allergy and Clinical Immunology
|
May 8, 2002
Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction
Barbro Dahlén, Annika Roquet, Mark D Inman, et al.
American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions
|
January 15, 2004
Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma
Eric D Bateman, Theo A Bantje, Maria João Gomes, et al.
The Journal of Allergy and Clinical Immunology
|
April 17, 2009
Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol
Ian D Pavord, Peter K Jeffery, Yusheng Qiu, et al.
Pulmonary Therapy
|
February 7, 2020
Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
Bernardino Alcázar Navarrete, Isabelle Boucot, Ian Naya, et al.
ERJ Open Research
|
October 11, 2018
Preventing clinically important deterioration with single-inhaler triple therapy in COPD
Ian Naya, Chris Compton, Afisi S Ismaila, et al.
Page
of 3